In the past several years, AMH assessment has gained widespread use in the clinical settings of several conditions including the prediction of ovarian response in women undergoing assisted reproduction treatment, assessment of PCOS, risk of ovarian hyperstimulation syndrome, prediction of menopause, and monitoring the impact of cytotoxic chemotherapy and radiotherapy on ovarian function (25). This evidence concerns the gene AMH and polycystic ovary syndrome.